An ongoing phase 1 study (NCT04572152) is evaluating the safety, anti-tumour activity and pharmacokinetics of AK119 in combination with an anti-PD-1/CTLA-4 bispecific antibody in advanced solid tumours (106). This evidence concerns the gene PDCD1 and neoplasm.